Adaptimmune Therapeutics
ADAP
ADAP was delisted on the 27th of October, 2025.
80 hedge funds and large institutions have $229M invested in Adaptimmune Therapeutics in 2022 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 26 increasing their positions, 24 reducing their positions, and 16 closing their positions.
8% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 24
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2.43% less ownership
Funds ownership: 72.71% → 70.28% (-2.4%)
6% less funds holding
Funds holding: 85 → 80 (-5)
19% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 16
36% less call options, than puts
Call options by funds: $191K | Put options by funds: $299K
46% less capital invested
Capital invested by funds: $426M → $229M (-$197M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LFCM
Long Focus Capital Management
San Juan,
Puerto Rico
|
+$6.12M |
| 2 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$4.38M |
| 3 |
ECM
Endurant Capital Management
San Mateo,
California
|
+$3.41M |
| 4 |
Renaissance Technologies
New York
|
+$1.44M |
| 5 |
Two Sigma Investments
New York
|
+$712K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
-$30M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$2.23M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$2.13M |
| 4 |
Millennium Management
New York
|
-$529K |
| 5 |
Morgan Stanley
New York
|
-$513K |
ADAP Hedge Fund Activity: Q1 2022 in Review
80 of the 6,361 institutional investors tracked by Wall St. Rank reported a position in Adaptimmune Therapeutics (ADAP) for Q1 2022, worth a combined $229M — down 46% from $426M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of ADAP and 13 opened new positions — a net loss of 3 holders — while 24 trimmed existing stakes and 26 added.
The largest buyer was Long Focus Capital Management, adding an estimated $6.12M. The largest seller was Capital World Investors, exiting entirely with an estimated $30M sold.
- 80 institutional investors held Adaptimmune Therapeutics (ADAP) as of Q1 2022, down from 85 in Q4 2021.
- Funds reported $229M of Adaptimmune Therapeutics stock for Q1 2022, down 46% quarter-over-quarter.
- 13 funds opened new Adaptimmune Therapeutics positions in Q1 2022 and 16 closed out, a net change of -3 holders.
- The largest Adaptimmune Therapeutics buyer in Q1 2022 was Long Focus Capital Management, an estimated $6.12M added.
- The largest Adaptimmune Therapeutics seller in Q1 2022 was Capital World Investors, an estimated $30M sold.
Based on aggregated 13F filings for Q1 2022.